Suppression of Rev3, the catalytic subunit of Pol zeta, sensitizes drug-resistant lung tumors to chemotherapy
Platinum-based chemotherapeutic drugs are front-line therapies for the treatment of non-small cell lung cancer. However, intrinsic drug resistance limits the clinical efficacy of these agents. Recent evidence suggests that loss of the translesion polymerase, Polζ [Pol zeta], can sensitize tumor cell...
| Main Authors: | , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | en_US |
| Published: |
National Academy of Sciences (U.S.)
2011
|
| Online Access: | http://hdl.handle.net/1721.1/64940 https://orcid.org/0000-0001-5785-8911 https://orcid.org/0000-0003-0179-9216 https://orcid.org/0000-0001-7243-8261 |